Get the Daily Brief
Latest Biotech News
Artios raises $115M: DNA damage‑response specialist funds clinic expansion
Artios Pharma closed an oversubscribed $115 million Series D to advance its DNA damage response (DDR) pipeline after delivering encouraging Phase I/IIa readouts for its lead programs. The...
Sofinnova closes €650M flagship fund: more dry powder for early biotech
Sofinnova Partners raised €650 million (~$750 million) for its Capital XI flagship fund, exceeding targets and earmarking capital for early‑stage therapeutics and medtech investments. Partners...
Nuvalent’s ALK drug posts durable responses: clinical rival to Pfizer’s Lorbrena
Nuvalent disclosed Phase 1/2 data for neladalkib in ALK‑positive lung cancer patients who progressed on prior ALK inhibitors, reporting a 31% overall response rate with many responses durable at...
J&J snaps up Halda for $3.05B — new anti-resistance approach added
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash, bringing Halda’s regulated induced proximity targeting chimera (RIPTAC) platform and lead candidate HLD‑0915 into...
Zanidatamab wins phase 3 — potential new HER2 standard in gastroesophageal cancer
Zymeworks’ zanidatamab (Ziihera®) produced statistically significant and clinically meaningful improvements in progression‑free survival in the Phase 3 HERIZON‑GEA‑01 trial versus trastuzumab plus...
Primates regain hand function — neural stem cell graft restores forelimb control
Two Nature Biotechnology papers report that transplantation of human embryonic stem cell‑derived spinal neural stem cells produced extensive restoration of forelimb function in rhesus monkeys with...
Fecal 'exfoliome' sequencing noninvasively tracks gut inflammation — Foli‑seq unveiled
Columbia University researchers published a targeted fecal exfoliated RNA method, Foli‑seq, that profiles host messenger RNA from exfoliated gut cells to monitor intestinal and immune activity in...
New sequencing hardware speeds cancer genomics — Roche, Thermo present platform advances
Early user data and demonstrations at the Association for Molecular Pathology show two instrument moves that could accelerate cancer genomic workflows. Roche previewed Axelios 1, a...
Solid licenses AAV‑SLB101 as AAV field readies next‑gen vectors
Solid Biosciences granted Andelyn Biosciences a non‑exclusive worldwide license to use Solid’s next‑generation capsid AAV‑SLB101, intended to enhance skeletal muscle and cardiac tropism while...
miRNA moves from wearables to exosomes: two new sensing and delivery advances
Two distinct advances spotlight microRNA’s dual role as a biomarker and therapeutic handle. Researchers reported engineered NK‑92 cell exosomes delivering miR‑124 that suppressed breast cancer...
AI predicts drug mechanisms and prioritizes molecules — DeepTarget, Terray unveil tools
Two computational advances aim to narrow the gap between in‑silico predictions and actionable drug development. Sanford Burnham and NIH teams released DeepTarget, which integrates drug and genetic...
Rapid diagnostics advance: Ocean Dx sepsis test and WHO clearance for BD HPV assay
A rapid assay from Ocean Dx reported 100% sensitivity and specificity versus blood culture in an early evaluation, detecting >1,000 bacterial species directly from whole blood and delivering...
Big biotech and VC cash returns: Artios $115M and Sofinnova’s €650M close
Investment momentum surfaced across early and mid‑stage biotech: Artios closed an oversubscribed $115 million Series D to advance its DNA damage response portfolio after positive Phase I/IIa data...
J&J pays $3.05B for Halda... buys new anti‑resistance cancer platform
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash to secure HLD‑0915 and the company’s RIPTAC "hold-and-kill" platform. The deal follows Halda’s phase 1/2 readout...
Ziihera tops trastuzumab: Phase 3 HERIZON-GEA‑01 posts PFS, OS gains
Zymeworks and partners Jazz Pharmaceuticals and BeOne announced positive topline results from the Phase 3 HERIZON‑GEA‑01 trial: zanidatamab (Ziihera) plus chemotherapy improved progression‑free...
Nuvalent’s ALK inhibitor posts durable responses — FDA path opens
Nuvalent released Phase 1/2 data for neladalkib in ALK‑positive lung cancer showing objective responses in patients who progressed on prior ALK inhibitors, with a reported overall response rate...
Solve Therapeutics raises $120M — ADC push lands Merck support
Solve Therapeutics closed a $120 million financing to advance its antibody‑drug conjugate (ADC) portfolio for solid tumors, citing backing from strategic pharma investors including Merck. The...
Artios closes $115M Series D — DNA damage repair programs advance
DNA damage response specialist Artios Ltd. raised $115 million in an oversubscribed Series D round to advance its first‑in‑class DDR programs after delivering encouraging Phase 1/IIa data for its...
Sofinnova closes €650M fund... extends early‑stage life‑science capital
Sofinnova Partners closed its Capital XI fund at €650 million (about $750 million), surpassing target and committing more capital to early‑stage biotech and medtech companies. Firm partners said...
Stem cell transplant restores hand function in monkeys... major translational step
A Nature Biotechnology report described extensive restoration of forelimb function in rhesus monkeys after transplanting human embryonic stem cell‑derived spinal cord neural stem cells...